Cell activation assay

Cell activation of B cells, T cells, NK cells, monocytes, and granulocytes can be simultaneously analyzed in our test system of fresh human whole blood.

Leverage the benefits of the unique test system ID.Flow®


We draw blood from donors directly at our test site allowing us to observe the effects of drugs on fresh, minimally manipulated whole blood. This provide invaluable insights into how drugs affect complex biological systems in the human blood including immune cells, platelets, immunoglobulins, the complement and cascade system,


ID.Flow provides a unique and physiologically relevant testing environment. It allows your test substance to be studied in a dynamic environment closely resembling human blood circulation.


FDA and EMA encourage the use of New Approach Methodologies (NAMs) to evaluate the immunotoxicity potential of new drugs and urge drug developers to choose non-animal methods when applicable.

Cell Activation

Biological drugs can have an immunomodulatory effect as part of their mode of action or be immunogenic, either of which can cause safety issues or modulate the drug’s therapeutic effect. It is therefore essential to know how your drug affects the immune system from both a safety and a functional perspective. Immuneed performs phenotypical analysis of all blood cell populations and subpopulations to analyze cell activation and depletion profiles. This includes neutrophils, monocytes, granulocytes, B-cells, T-cells, NK cells, platelets, and red blood cells. If you are interested in looking at the proliferation or differentiation of cells in the presence of your drug, we also offer to complement PBMC assays. If you are unsure which blood cells your drug binds to, our platform (ID.Flow) also provides a unique opportunity to track the binding of different blood cell populations simultaneously.

“Our lab team has vast experience in flow cytometry analyzing Neutrophils, Monocytes, Granulocytes, B-cells T-cells, NK cells Platelets and, Red blood cells.”

Cell binding by ID.Flow

Freshly acquired whole blood was incubated with anti-integrin alpha 4  (2 µg/ml) or vehicle usingID.Flow. Blood was acquired directly after collection (zero time point) and at the 4-hour time point was stained with fluorescently labeled monoclonal antibodies to detect: erythrocytes (CD235ab+, CD45-), platelets (CD41+, CD45-), T cells (CD3+), B cells (CD19+), NK cells (CD56+), monocytes (CD14+) and granulocytes (CD66b+).

Cell activation profiles by ID.Flow

The graphs to the left show data from one of our studies on fresh blood from healthy donors, where the effect of two different antibodies was studied. One of the antibodies targets CD52 and induces activation of T-cells and monocytes. The other antibody targets EGFR, and does not induce activation of T-cells or monocytes and thus displays an activation profile similar to the vehicle buffer.